Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (170)

Search Parameters:
Keywords = syndromic aortic diseases

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
20 pages, 2027 KiB  
Review
SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology
by Marlena Stielow, Łukasz Fijałkowski, Aidas Alaburda, Grzegorz Grześk, Elżbieta Grześk, Jacek Nowaczyk and Alicja Nowaczyk
Molecules 2025, 30(15), 3112; https://doi.org/10.3390/molecules30153112 - 25 Jul 2025
Viewed by 882
Abstract
Studies have shown that sodium-glucose cotransporter type 2 (SGLT2) inhibitors not only help lower blood glucose levels but also offer cardioprotective effects, reduce the progression of heart failure, and may even slow the progression of aortic stenosis. The mechanisms of these beneficial properties [...] Read more.
Studies have shown that sodium-glucose cotransporter type 2 (SGLT2) inhibitors not only help lower blood glucose levels but also offer cardioprotective effects, reduce the progression of heart failure, and may even slow the progression of aortic stenosis. The mechanisms of these beneficial properties are thought to involve multiple pathways, including reducing inflammation, oxidative stress, and improving cellular energy metabolism. Advancing knowledge about the mechanisms of action of these drugs and their effects on the course of the aforementioned diseases has become the subject of intensive clinical and scientific research. This publication aims to provide insight into the role of SGLT2 inhibitors in the context of diabetes mellitus, heart failure and acute coronary syndrome, through clinical analysis, mechanistic insights and comparison of the effects of these drugs. Full article
(This article belongs to the Special Issue Organic Molecules in Drug Discovery and Development)
Show Figures

Figure 1

12 pages, 408 KiB  
Article
Overweight and Obesity in Adults with Congenital Heart Disease and Heart Failure: Real-World Evidence from the PATHFINDER-CHD Registry
by Robert D. Pittrow, Harald Kaemmerer, Annika Freiberger, Stefan Achenbach, Gert Bischoff, Oliver Dewald, Peter Ewert, Anna Engel, Sebastian Freilinger, Jürgen Hörer, Stefan Holdenrieder, Michael Huntgeburth, Ann-Sophie Kaemmerer-Suleiman, Leonard B. Pittrow, Renate Kaulitz, Frank Klawonn, Fritz Mellert, Nicole Nagdyman, Rhoia C. Neidenbach, Wolfgang Schmiedeberg, Benjamin A. Pittrow, Elsa Ury, Fabian von Scheidt, Frank Harig and Mathieu N. Suleimanadd Show full author list remove Hide full author list
J. Clin. Med. 2025, 14(13), 4561; https://doi.org/10.3390/jcm14134561 - 27 Jun 2025
Viewed by 519
Abstract
Background: The PATHFINDER-CHD Registry is a prospective, multicenter, non-interventional registry across tertiary care centers in Germany. The aim is to analyze real-world data on adults with congenital heart defects (ACHD) or hereditary connective tissue disorders who have manifest heart failure (HF), a history [...] Read more.
Background: The PATHFINDER-CHD Registry is a prospective, multicenter, non-interventional registry across tertiary care centers in Germany. The aim is to analyze real-world data on adults with congenital heart defects (ACHD) or hereditary connective tissue disorders who have manifest heart failure (HF), a history of HF, or are at significant risk of developing HF. This analysis investigates the prevalence and clinical impact of overweight and obesity in this unique population. Methods: As of 1st February, 2025, a total of 1490 ACHD had been enrolled. The mean age was 39.4 ± 12.4 years, and 47.9% were female. Patients were categorized according to Perloff’s functional class and the Munich Heart Failure Classification for Congenital Heart Disease (MUC-HF-Class). Results: The most common congenital heart disease (CHD) in this cohort was Tetralogy of Fallot, transposition of the great arteries, and congenital aortic valve disease. Marfan syndrome was the most common hereditary connective tissue disease. Of the patients, 46.1% were classified as overweight (32.8%) or obese (13.3%), while 4.8% were underweight. The highest prevalence of overweight (47.1%) was observed among patients who had undergone palliative surgery, whereas untreated patients showed the highest proportion of normal weight (57.2%). Cyanotic patients were predominantly of normal weight. Patients with univentricular circulation exhibited significantly lower rates of overweight and obesity (35%; p = 0.001). Overweight and obesity were statistically significantly associated with arterial hypertension, diabetes mellitus, and sleep apnea (all p < 0.001). High BMI was linked to increased use of HF-specific medications, including SGLT2 inhibitors (p = 0.040), diuretics (p = 0.014), and angiotensin receptor blockers (p = 0.005). Conclusions: The data highlight the clinical relevance of overweight and obesity in ACHD with HF, emphasizing the need for individualized prevention and treatment strategies. The registry serves as a critical foundation for the optimization of long-term care in this population. Full article
(This article belongs to the Section Cardiology)
Show Figures

Figure 1

14 pages, 2111 KiB  
Review
Mitral Annular Calcification, a Not So Marginal and Relatively Benign Finding as Many of Us Think: A Review
by András Vereckei, Zsigmond Jenei, Hajnalka Vágó, Dorottya Balla, Alexisz Panajotu, Andrea Nagy and Gábor Katona
J. Cardiovasc. Dev. Dis. 2025, 12(6), 233; https://doi.org/10.3390/jcdd12060233 - 18 Jun 2025
Viewed by 558
Abstract
Mitral annular calcification (MAC) is usually considered an incidental, benign, age-related finding without serious complications in patients evaluated for cardiovascular or pulmonary disease with imaging studies that may result in mitral regurgitation or stenosis when severe. Therefore, it is usually not considered a [...] Read more.
Mitral annular calcification (MAC) is usually considered an incidental, benign, age-related finding without serious complications in patients evaluated for cardiovascular or pulmonary disease with imaging studies that may result in mitral regurgitation or stenosis when severe. Therefore, it is usually not considered a significant alteration. However, there is accumulating evidence that it is associated with a higher risk of cardiovascular events, such as atherosclerotic coronary artery disease, aortic artery disease, carotid artery disease, peripheral artery disease, stroke, atrial fibrillation, atrioventricular and/or intraventricular conduction disturbance, systemic embolization, infective endocarditis, heart failure and mortality. The presence of MAC also significantly influences the outcome of mitral valve transcatheter and surgical interventions. Several conditions may predispose to MAC. MAC is strongly related to cardiovascular risk factors, such as hypertension, diabetes, smoking and cardiovascular atherosclerosis, and inflammation may also play a role in the pathogenesis of MAC. Also, conditions that increase mitral valve stress, such as hypertension, aortic stenosis and hypertrophic cardiomyopathy, predispose to accelerated degenerative calcification of the mitral annulus area. Congenital disorders, e.g., Marfan syndrome and Hurler syndrome, are also associated with MAC, due to an intrinsic abnormality of the connective tissue composing the annulus. Full article
(This article belongs to the Section Imaging)
Show Figures

Figure 1

11 pages, 227 KiB  
Article
Extracellular Matrix Tissue Patch for Aortic Arch Repair in Pediatric Cardiac Surgery: A Single-Center Experience
by Marcin Gładki, Anita Węclewska, Paweł R. Bednarek, Tomasz Urbanowicz, Anna Olasińska-Wiśniewska, Bartłomiej Kociński and Marek Jemielity
J. Clin. Med. 2025, 14(11), 3955; https://doi.org/10.3390/jcm14113955 - 3 Jun 2025
Viewed by 560
Abstract
Introduction: Among aortic diseases in children, congenital defects such as coarctation of the aorta (CoA), interrupted aortic arch (IAA), hypoplastic aortic arch (HAA), and hypoplastic left heart syndrome (HLHS) predominate. Tissue patches are applied in pediatric cardiovascular surgery for the repair of [...] Read more.
Introduction: Among aortic diseases in children, congenital defects such as coarctation of the aorta (CoA), interrupted aortic arch (IAA), hypoplastic aortic arch (HAA), and hypoplastic left heart syndrome (HLHS) predominate. Tissue patches are applied in pediatric cardiovascular surgery for the repair of congenital aortic defects as a filling material to replenish missing tissue or as a substitute material for the complete reconstruction of the vascular wall along the course of the vessel. This retrospective single-center study aimed to present the safety and feasibility of extracellular matrix (ECM) biological scaffolds in pediatric aortic surgery. Patients and methods: There were 26 patients (17 newborns and nine children), who underwent surgical procedures in the Department of Pediatric Cardiac Surgery (Poznań, Poland) between 2023 and 2024. The patients’ population was divided into two subgroups according to the hemodynamic nature of the primary diagnosis of the congenital heart defect and the performed pediatric cardiovascular surgery. The first group included 18 (72%) patients after aortic arch repair for interrupted aortic arch and/or hypoplastic aortic arch, while the second group included seven (28%) patients after aortopulmonary anastomosis. In the first group, patches were used to reconstruct the aortic arch by forming an artificial arch with three separate patches sewn together, primarily addressing the hypoplastic or interrupted segments. In the second group, patches were applied to augment the anastomosis site between the pulmonary trunk and the aortic arch, specifically at the connection points in procedures, such as the Damus–Kaye–Stansel or Norwood procedures. The analysis was based on data acquired from the national cardiac surgery registry. Results: The overall mortality in the presented group was 15%. All procedures were performed using median sternotomy with a cardiopulmonary bypass. The cardiopulmonary bypass (CPB) and aortic cross-clamp (AoX) median times were 144 (107–176) and 53 (33–79) min, respectively. There were two (8%) cases performed in deep hypothermic circulatory arrest (DHCA). The median postoperative stay in the intensive care unit (ICU) was 284 (208–542) h. The median mechanical ventilation time was 226 (103–344) h, including 31% requiring prolonged mechanical ventilation support. Postoperative acute kidney failure requiring hemodiafiltration (HDF) was noticed in 12% of cases. Follow-up data, collected via routine transthoracic echocardiography (TTE) and clinical assessments over a median of 418 (242.3–596.3) days, showed no evidence of patch-related complications such as restenosis, aneurysmal dilation, or calcification in surviving patients. One patient required reintervention on the same day due to a significantly narrow ascending aorta, unrelated to patch failure. No histological data from explanted patches were available, as no patches were removed during the study period. The median (Q1–Q3) hospitalization time was 21 (16–43) days. Conclusions: ProxiCor® biological patches derived from the extracellular matrix can be safely used in pediatric patients with congenital aortic arch disease. Long-term follow-up is necessary to confirm the durability and growth potential of these patches, particularly regarding their resistance to calcification and dilation. Full article
(This article belongs to the Special Issue Clinical Management of Pediatric Heart Diseases)
17 pages, 1724 KiB  
Review
The Diversity of Fibrillin Functions: Lessons from the Periodontal Ligament
by Elisabeth Genot, Tala Al Tabosh, Sylvain Catros, Florian Alonso and Damien Le Nihouannen
Cells 2025, 14(11), 764; https://doi.org/10.3390/cells14110764 - 22 May 2025
Viewed by 658
Abstract
Marfan syndrome is caused by a mutation in the FBN1 gene encoding fibrillin-1. This extracellular matrix glycoprotein, which assembles into microfibrils, is best known for its scaffolding role in the production of elastic fibers responsible for connective tissue elasticity and tensile strength. Research [...] Read more.
Marfan syndrome is caused by a mutation in the FBN1 gene encoding fibrillin-1. This extracellular matrix glycoprotein, which assembles into microfibrils, is best known for its scaffolding role in the production of elastic fibers responsible for connective tissue elasticity and tensile strength. Research into Marfan syndrome mainly focuses on the pathophysiology involved in the degeneration of elastin-rich elastic fibers, which are essential components of the aortic wall. However, fibrillin-1 also exists in elastin-poor (elaunin) or elastin-free (oxytalan) microfibril bundles that were first described in the periodontal ligament (PDL). This dynamic, densely cellular, and highly vascularized tissue anchors teeth in their bone sockets and acts as a protective shock absorber during chewing. Current knowledge suggests that fibrillin microfibrils mechanically support blood vessels in the PDL and ensure their proper functioning. However, many more insights on the roles of fibrillin, especially independently of elastin, can be extracted from this tissue. Here, we review the phenotypic and functional characteristics of the PDL in connection with fibrillin-1, focusing on those related to microvessels. This review aims to shed light on this often-overlooked fibrillin-rich resource as a model for future studies investigating fibrillin functions in health and Marfan disease. Full article
(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Marfan Syndrome)
Show Figures

Graphical abstract

23 pages, 2645 KiB  
Article
Baricitinib and Lonafarnib Synergistically Target Progerin and Inflammation, Improving Lifespan and Health in Progeria Mice
by Peter Krüger, Moritz Schroll, Felix Quirin Fenzl, Ramona Hartinger, Eva-Maria Lederer, Agnes Görlach, Leslie B. Gordon, Paola Cavalcante, Nicola Iacomino, Birgit Rathkolb, Juan Antonio Aguilar Pimentel, Manuela Östereicher, Nadine Spielmann, Cordula Maria Wolf, Martin Hrabe de Angelis and Karima Djabali
Int. J. Mol. Sci. 2025, 26(10), 4849; https://doi.org/10.3390/ijms26104849 - 19 May 2025
Viewed by 1171
Abstract
Hutchinson–Gilford progeria syndrome (HGPS) is a rare, fatal, and premature aging disorder caused by progerin, a truncated form of lamin A that disrupts nuclear architecture, induces systemic inflammation, and accelerates senescence. While the farnesyltransferase inhibitor lonafarnib extends the lifespan by limiting progerin farnesylation, [...] Read more.
Hutchinson–Gilford progeria syndrome (HGPS) is a rare, fatal, and premature aging disorder caused by progerin, a truncated form of lamin A that disrupts nuclear architecture, induces systemic inflammation, and accelerates senescence. While the farnesyltransferase inhibitor lonafarnib extends the lifespan by limiting progerin farnesylation, it does not address the chronic inflammation or the senescence-associated secretory phenotype (SASP), which worsens disease progression. In this study, we investigated the combined effects of baricitinib (BAR), a JAK1/2 inhibitor, and lonafarnib (FTI) in a LmnaG609G/G609G mouse model of HGPS. BAR + FTI therapy synergistically extended the lifespan by 25%, surpassing the effects of either monotherapy. Treated mice showed improved health, as evidenced by reduced kyphosis, better fur quality, decreased incidence of cataracts, and less severe dysgnathia. Histological analyses indicated reduced fibrosis in the dermal, hepatic, and muscular tissues, restored cellularity and thickness in the aortic media, and improved muscle fiber integrity. Mechanistically, BAR decreased the SASP and inflammatory markers (e.g., IL-6 and PAI-1), complementing the progerin-targeting effects of FTI. This preclinical study demonstrates the synergistic potential of BAR + FTI therapy in addressing HGPS systemic and tissue-specific pathologies, offering a promising strategy for enhancing both lifespan and health. Full article
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Show Figures

Figure 1

25 pages, 2566 KiB  
Article
Early Risk Prediction in Acute Aortic Syndrome on Clinical Data Using Machine Learning
by Mehdi Tavafi, Kalpdrum Passi and Robert Ohle
Algorithms 2025, 18(5), 257; https://doi.org/10.3390/a18050257 - 28 Apr 2025
Viewed by 792
Abstract
This study explores machine learning’s potential for early Acute Aortic Syndrome (AAS) prediction by integrating and cleaning extensive clinical datasets from 68 emergency departments in the USA, covering the medical histories of nearly 150,000 patients from 2021 to 2022. Utilizing various data-splitting strategies [...] Read more.
This study explores machine learning’s potential for early Acute Aortic Syndrome (AAS) prediction by integrating and cleaning extensive clinical datasets from 68 emergency departments in the USA, covering the medical histories of nearly 150,000 patients from 2021 to 2022. Utilizing various data-splitting strategies and classifiers, the research constructs predictive models and addresses dataset size limitations, achieving an exceptional accuracy of 99.3% with the Relief feature method and random forest classifier, facilitating further research on AAS and other cardiovascular diseases. Full article
Show Figures

Figure 1

20 pages, 20625 KiB  
Review
Sudden Cardiac Death in Pregnant Women—Literature Review and Autopsy Findings
by Ioana Radu, Anca Otilia Farcas, Laura Cimpan, Corina-Lacramioara Platon, Victoria Nyulas, Bogdan Andrei Suciu, Ioana Hălmaciu, Carmen Corina Radu and Klara Brînzaniuc
Diagnostics 2025, 15(9), 1108; https://doi.org/10.3390/diagnostics15091108 - 27 Apr 2025
Viewed by 1287
Abstract
Cardiovascular diseases increase among pregnant women and complicate 1–4% of pregnancies worldwide. The incidence of maternal deaths due to cardiovascular causes has increased dramatically, rising from 3% three decades ago to 15% in recent years. The aim of this study is to provide [...] Read more.
Cardiovascular diseases increase among pregnant women and complicate 1–4% of pregnancies worldwide. The incidence of maternal deaths due to cardiovascular causes has increased dramatically, rising from 3% three decades ago to 15% in recent years. The aim of this study is to provide a comprehensive overview of the current status of knowledge in sudden maternal death (SMD) described in the literature and to present two cases of autopsy findings in sudden cardiac death in pregnant women. Among the most common causes of sudden maternal deaths are peripartum cardiomyopathies, aortic dissection, acute myocardial infarction, arrhythmias, ischemic heart disease, and coronary artery dissection, and among the less common causes, we list coronary artery dissection, congenital heart diseases, valvulopathies, hypertension, fibroelastosis, and borderline myocarditis. The Centers for Disease Control and Prevention (CDC) reported that over 80% of pregnancy-related deaths were preventable. To reduce the number of maternal deaths caused by cardiovascular diseases, the implementation of specialized multidisciplinary teams has been proposed. Molecular biology techniques are proving their effectiveness in forensic medicine. PCR or DNA sequencing can be utilized in “molecular autopsy”, which holds particular value in cases of sudden death where the forensic autopsy is negative but there is a suspicion that death was caused by arrhythmia. Susceptibility genes can be analyzed, such as KCNQ1, KCNH2, KCNE1, and KCNE2, which are involved in long QT syndrome, the RYR2 gene implicated in catecholaminergic polymorphic ventricular tachycardia type 1, or the SCN5A gene associated with Brugada syndrome. Early identification of risk factors involved in sudden maternal death prenatally and during pregnancy is essential. At the same time, genetic determinations and molecular biology techniques are absolutely necessary to prevent the occurrence of sudden deaths among close relatives. Full article
(This article belongs to the Special Issue Diagnosis and Management of Cardiovascular Disorders)
Show Figures

Figure 1

9 pages, 516 KiB  
Article
Beyond the Echo: Is Comprehensive Vascular Exploration Valuable in Cases of Non-Syndromic Thoracic Aortic Aneurysms or Bicuspid Aortic Valve?
by Austin Saugstad, Srekar Ravi, George Bcharah, Christine E. Firth, Hend Bcharah, Hussein Abdul Nabi, Hoang Nhat Pham, Ramzi Ibrahim, Sant J. Kumar, Mahmoud Abdelnabi, Linnea M. Baudhuin, Yuxiang Wang, Mayowa A. Osundiji and Fadi Shamoun
J. Cardiovasc. Dev. Dis. 2025, 12(5), 167; https://doi.org/10.3390/jcdd12050167 - 24 Apr 2025
Viewed by 620
Abstract
Bicuspid aortic valve (BAV) and thoracic aortic aneurysms and dissections (TAAD) are recognized in syndromic connective tissue diseases (CTD), but most cases occur sporadically. The extent to which non-syndromic BAV or TAAD predisposes to additional arteriopathies, particularly in younger individuals, remains unclear. We [...] Read more.
Bicuspid aortic valve (BAV) and thoracic aortic aneurysms and dissections (TAAD) are recognized in syndromic connective tissue diseases (CTD), but most cases occur sporadically. The extent to which non-syndromic BAV or TAAD predisposes to additional arteriopathies, particularly in younger individuals, remains unclear. We retrospectively analyzed 1438 patients (mean age = 48.0, 67.7% female), excluding those with CTDs. Participants were ≤60 years old and categorized by the presence of BAV and/or TAAD. We examined co-existing arterial pathologies, including fibromuscular dysplasia, spontaneous coronary artery dissection, abdominal aortic aneurysms (AAA), mesenteric, peripheral extremity, and carotid/cerebral arteriopathies. Overall, 44.6% had either BAV or TAAD, and 27.2% had multiple arteriopathies. While vascular diseases were frequently noted, odds ratios demonstrated no significantly increased risk of extra-aortic arteriopathies in the BAV or TAAD cohorts. AAA exhibited a non-significant trend toward higher prevalence in TAAD patients. These findings support current guidelines recommending targeted imaging (transthoracic echocardiography of the aortic root and ascending aorta) over comprehensive “head-to-pelvis” screening for non-syndromic BAV or TAAD patients without additional risk factors. Ongoing genetic analyses may elucidate whether particular variants predispose to multi-site aneurysms or dissections. Consequently, targeted surveillance remains appropriate, with broader imaging reserved for patients with genetic or clinical indicators of higher risk. Full article
(This article belongs to the Special Issue Models and Methods for Computational Cardiology: 2nd Edition)
Show Figures

Figure 1

14 pages, 855 KiB  
Article
PNPLA3 Polymorphism Is Inversely Correlated with Aortic Stiffness in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Without Fibrosis
by Barbara Toffoli, Consuelo Comar, Andrea Grillo, Vincenzo Barbato, Emanuele Vincis, Veronica Baldi, Silvia Berti, Teresa Volpato, Francesca Zorat, Saveria Lory Crocè, Giacomo Emmi, Bruno Fabris, Massimo Puato and Stella Bernardi
Int. J. Mol. Sci. 2025, 26(7), 3256; https://doi.org/10.3390/ijms26073256 - 1 Apr 2025
Viewed by 744
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) corresponds to the condition of increased hepatic fat levels, which is the leading cause of hepatic failure and carcinoma. It is also an independent risk factor for cardiovascular disease (CVD) and mortality. MASLD can be due to [...] Read more.
Metabolic dysfunction-associated steatotic liver disease (MASLD) corresponds to the condition of increased hepatic fat levels, which is the leading cause of hepatic failure and carcinoma. It is also an independent risk factor for cardiovascular disease (CVD) and mortality. MASLD can be due to obesity with insulin resistance and/or genetic predisposition, i.e., polymorphism in the patatin-like phospholipase domain-containing 3 (PNPLA3) gene. PNPLA3 polymorphism has been associated with increased hepatic fat levels, fibrosis, cirrhosis, and hepatocellular carcinoma, while its association with CVD remains to be fully understood. The aim of the current study was to examine whether the vascular phenotype of patients with MASLD differed between carriers and noncarriers of the PNPLA3 polymorphism. Adult patients with MASLD underwent clinical assessment, PNPLA3 genotyping, arterial tonometry for aortic stiffness measurement, and ultrasound examination of carotid arteries. In total, 117 patients with MASLD and no fibrosis (median hepatic stiffness was 4.71 kPa) were recruited. Carriers of the PNPLA3 polymorphism were younger and exhibited higher levels of ALT and APRI, as compared to wild-type subjects. On the other hand, carriers of the PNPLA3 polymorphism had not only a better metabolic profile (i.e., lower glucose and glycated hemoglobin) but also lower blood pressure, carotid intima-media thickness (IMT), and cardiovascular risk. In addition, PNPLA3 polymorphism was negatively correlated with aortic stiffness, which is a marker of arteriolosclerosis and vascular ageing. Our data are consistent with previous observations that in case of genetically-driven MASLD, there is an inverse association with common predictors of CVD. Our data support the view that the main contributors to CVD risk in patients with MASLD remain conventional cardiometabolic risk factors (i.e., age, glucose) that are more likely to be found in metabolic syndrome-related MASLD rather than genetically-driven MASLD, at least in the first stages of the disease. Full article
Show Figures

Figure 1

15 pages, 7229 KiB  
Article
Genotype-Phenotype Correlation Insights Through Molecular Modeling Analysis in a Patient with Loeys-Dietz Syndrome
by Galateia Stathori, Eleni Koniari, Dimitrios Vlachakis, Eleni Papanikolaou, George P. Chrousos and Christos Yapijakis
Genes 2025, 16(4), 357; https://doi.org/10.3390/genes16040357 - 21 Mar 2025
Viewed by 663
Abstract
Background: Pathogenic variants within the gene encoding transforming growth factor β (TGF-β) are responsible for Loeys-Dietz syndrome (LDS), a heritable thoracic aortic disease sharing clinical features with Marfan syndrome, including craniofacial and skeletal abnormalities as well as aortic root aneurysms and dissections. In [...] Read more.
Background: Pathogenic variants within the gene encoding transforming growth factor β (TGF-β) are responsible for Loeys-Dietz syndrome (LDS), a heritable thoracic aortic disease sharing clinical features with Marfan syndrome, including craniofacial and skeletal abnormalities as well as aortic root aneurysms and dissections. In contrast to Marfan syndrome patients, who rarely develop aneurysms or dissections beyond the aortic root, LDS patients frequently exhibit vessel aneurysms in locations other than the aortic root. Here, we report the case of a 61-year-old patient who initially presented with marfanoid characteristics and an aortic root aneurysm and was presumed to have Marfan syndrome two decades ago. Later, the patient developed an abdominal aorta aneurysm, necessitating endovascular repair and stent placement. That fact raised doubts regarding the initial diagnosis of Marfan syndrome, and we decided to investigate the genetic cause of the disorder. Methods: Genetic testing was performed using WES analysis and Sanger sequencing. Results: The genetic analysis detected a de novo heterozygous pathogenic variant c.896G>A in exon 5 of the TGFB2 gene, resulting in the amino acid substitution p. Arg299Gln that has devastating destabilizing structural effects on 3D folding of the protein, as demonstrated by the molecular modeling study we performed. This variant is pathogenic for LDS type 4, partially consistent with the patient’s clinical presentation. Conclusions: Our case emphasizes the significance of precise clinical assessment and genetic verification in patients exhibiting marfanoid characteristics. Furthermore, our findings contribute to the understanding of the diverse clinical spectrum associated with this specific pathogenic variant of TGFB2, underscoring the importance of detailed clinical assessment in expanding knowledge of genotype-phenotype correlations. Accurate diagnosis is crucial for tailored and appropriate management of individuals with heritable thoracic aortic diseases. Full article
(This article belongs to the Special Issue Advances in Craniofacial Genetics)
Show Figures

Figure 1

12 pages, 2423 KiB  
Article
Predictors of Diagnostic Inaccuracy of Detecting Coronary Artery Stenosis by Preprocedural CT Angiography in Patients Prior to Transcatheter Aortic Valve Implantation
by Matthias Renker, Steffen D. Kriechbaum, Stefan Baumann, Christian Tesche, Grigorios Korosoglou, Efstratios I. Charitos, Birgid Gonska, Tim Seidler, Yeong-Hoon Choi, Andreas Rolf, Won-Keun Kim and Samuel T. Sossalla
Diagnostics 2025, 15(6), 771; https://doi.org/10.3390/diagnostics15060771 - 19 Mar 2025
Viewed by 842
Abstract
Background: The diagnostic performance of preprocedural CT angiography in detecting coronary artery disease (CAD) in patients scheduled for transcatheter aortic valve implantation (TAVI) has been reported. However, data on predictors of diagnostic inaccuracy are sparse. We sought to investigate clinical characteristics and imaging [...] Read more.
Background: The diagnostic performance of preprocedural CT angiography in detecting coronary artery disease (CAD) in patients scheduled for transcatheter aortic valve implantation (TAVI) has been reported. However, data on predictors of diagnostic inaccuracy are sparse. We sought to investigate clinical characteristics and imaging criteria that predict the inaccurate assessment of coronary artery stenosis based on pre-TAVI-CT. Methods: The patient- and vessel-level analysis of all CT datasets from 192 patients (mean age 82.1 ± 4.8 years; 63.5% female) without known CAD or severe renal dysfunction was performed retrospectively in a blinded fashion. Significant CAD was defined as a CAD-RADS™ 2.0 category ≥ 4 by CT. Invasive coronary angiography (ICA) served as the reference standard for relevant CAD (≥70% luminal diameter stenosis or fractional flow reserve ≤ 0.80). Pertinent clinical characteristics and imaging criteria of all true-positive (n = 71), false-positive (n = 30), false-negative (n = 4), and true-negative patient-level CT diagnoses (n = 87) for relevant stenosis according to ICA were assessed. Results: In the univariate per-patient analysis, the following parameters yielded discriminative power (p < 0.10) regarding inaccurate CAD assessment by pre-TAVI-CT: age, atrial fibrillation, scanner generation, and image quality. Factors independently associated with CT diagnostic inaccuracy were determined using multivariable logistic regression analysis: a younger age (odds ratio [OR] 0.87; 95% confidence interval [CI] 0.80 to 0.94; p < 0.01) and insufficient CT image quality (OR 0.6; CI 0.41 to 0.89; p < 0.01). Conclusions: Our results demonstrate younger age and poor CT image quality to predict less accurate CAD assessments by pre-TAVI-CT in comparison with ICA. Knowledge of these predictors may aid in more efficient coronary artery interpretations based on pre-TAVI-CT. Full article
(This article belongs to the Special Issue Novelty and Challenge in CT Angiography)
Show Figures

Figure 1

18 pages, 707 KiB  
Review
Exploring Disparities in Atherosclerosis Comorbidity with Aortic Aneurysm
by Aksana N. Kucher, Iuliia A. Koroleva and Maria S. Nazarenko
Biomedicines 2025, 13(3), 593; https://doi.org/10.3390/biomedicines13030593 - 1 Mar 2025
Viewed by 1243
Abstract
Aortic aneurysm (AA) and atherosclerosis (AS) of various vascular beds are asymptomatic for a long time and are relatively common pathological conditions that lead to life-threatening and disabling complications. In this review, we discuss the current understanding of the high variation in direct [...] Read more.
Aortic aneurysm (AA) and atherosclerosis (AS) of various vascular beds are asymptomatic for a long time and are relatively common pathological conditions that lead to life-threatening and disabling complications. In this review, we discuss the current understanding of the high variation in direct and inverse comorbidity of AA and AS as presented in scientific publications. Estimates of AA and AS comorbidity depend on several factors, such as the location of AA (ascending or descending thoracic aorta or abdominal aorta), familial or sporadic cases of AA, syndromic forms of AA, and/or aortic valve pathology (bicuspid aortic valve [BAV]). To identify the causes of the comorbidity of AA and AS, it is important to consider and characterise many factors in detail. These factors include clinical characteristics of the patients included in a study (age, sex) and risk factors (mainly the presence of monogenic forms and BAV, hypertension, hypercholesterolaemia, diabetes mellitus, and cigarette smoking). Additionally, it is essential to consider characteristics of the disease course and the nature of multimorbidity and to take into account pathologies not only of the cardiovascular system but also of other organ systems, with special attention to metabolic and endocrine disorders. Full article
Show Figures

Figure 1

11 pages, 807 KiB  
Communication
Fibrinogen-to-Albumin Ratio as Predictor of Mortality in Acute Aortic Syndromes
by Alexandra Julia Lipa, Patrick Andreikovits, Marco Stoeckl, Hans Domanovits, Christian Schoergenhofer, Michael Schwameis and Juergen Grafeneder
J. Clin. Med. 2025, 14(5), 1669; https://doi.org/10.3390/jcm14051669 - 1 Mar 2025
Viewed by 770
Abstract
Background: Acute aortic syndrome (AAS) is a life-threatening condition characterized by a high mortality, yet reliable prognostic biomarkers are still lacking. The fibrinogen-to-albumin ratio (FAR) has recently gained attention in cardiovascular research but has not been explored in the context of AAS. This [...] Read more.
Background: Acute aortic syndrome (AAS) is a life-threatening condition characterized by a high mortality, yet reliable prognostic biomarkers are still lacking. The fibrinogen-to-albumin ratio (FAR) has recently gained attention in cardiovascular research but has not been explored in the context of AAS. This study assessed the association between the FAR and 30-day mortality in AAS patients who presented to the emergency department. Methods: We included all AAS patients aged 18 years and older who presented to the emergency department between 2013 and 2021. The outcome measured was 30-day all-cause mortality. Cox regression analysis assessed the relationship between the FAR and the outcome. Results: A total of 171 patients (mean age 67, SD 13.7; 33% female) were included, with 68 (40%) dying within 30 days of admission. Non-survivors had a significantly lower FAR (mean 8.9, SD 4.97) than survivors (mean 10.8, SD 5.44, p = 0.02). FAR was significantly associated with 30-day mortality (crude HR 0.935, 95% CI 0.88–0.99, p = 0.02). This association remained significant after adjusting for age, sex, cardiopulmonary resuscitation, catecholamine administration, bleeding on admission, and type of AAS (adjusted HR 0.92, 95% CI 0.87–0.98, p = 0.01). Conclusions: FAR was independently associated with 30-day mortality in AAS patients who presented to the emergency department. Given its simplicity and cost-effectiveness, it could be a valuable biomarker, especially in resource-limited settings, to improve risk assessment and optimize resource allocation in AAS. Full article
(This article belongs to the Special Issue Aortic Pathologies: Aneurysm, Atherosclerosis and More)
Show Figures

Figure 1

19 pages, 26334 KiB  
Article
Computational Fluid Dynamics-Driven Comparison of Endovascular Treatment Strategies for Penetrating Aortic Ulcer
by Katia Capellini, Emanuele Gasparotti, Vincenzo Castiglione, Cataldo Palmieri, Sergio Berti, Antonio Rizza and Simona Celi
J. Clin. Med. 2025, 14(4), 1290; https://doi.org/10.3390/jcm14041290 - 15 Feb 2025
Viewed by 737
Abstract
Background: Penetrating aortic ulcer (PAU) is an acute aortic syndrome characterized by a high rupture risk. There are several PAU-treatment procedures indicated for the management of this pathology associated with different effects on vessel morphology and hemodynamics. A deep evaluation of the different [...] Read more.
Background: Penetrating aortic ulcer (PAU) is an acute aortic syndrome characterized by a high rupture risk. There are several PAU-treatment procedures indicated for the management of this pathology associated with different effects on vessel morphology and hemodynamics. A deep evaluation of the different types of treatment may be helpful in decision making. Computational Fluid Dynamics (CFD) is a powerful tool for detailed inspection of cardiovascular diseases. The aim of this work was to implement a comparative analysis based on CFD evaluation of the effects of two type of PAU treatments. Methods: Thoracic endovascular aortic repair (TEVAR) with a left subclavian artery (LSA) branched aortic endograft (SBSG) and a hybrid approach including TEVAR and carotid-LSA bypass were considered. Aortic anatomical models were created from computed tomography (CT) images acquired before and after PAU treatment with SBSG for three patients. Starting from these models, a new aortic geometry corresponding to the outcome of the hybrid strategy was generated. Morphological analysis and CFD simulations were carried out for all aortic models to evaluate LSA outflow for the same predefined boundary conditions. Results: Reductions in LSA diameter were found between aortic models before and after the SBSG (18.2%, 20.8%, and 12.4% for CASE 1, CASE 2, and CASE 3, respectively). The flow rate at LSA changed between pre-configuration and aortic configuration after the PAU treatments: an averaged decrement of 1.08% and 7.5% was found for SBSG and the hybrid approach, respectively. The larger increase in pressure drop between the aortic arch and the LSA extremity was shown in the hybrid approach for all cases. Conclusions: CFD simulations suggest that SBSG preserves LSA perfusion more than a hybrid strategy and has less impact on thoracic aorta hemodynamics. Full article
Show Figures

Figure 1

Back to TopTop